Tibotec to seek once-a-day Prezista regimen for experienced patients
23 February 2010
Katie McQue
Please Login to read the full article.
23 February 2010
Katie McQue
katie.mcque@informa.com
Tibotec (Johnson & Johnson) has shown that a once-daily regimen of its HIV protease inhibitor Prezista (darunavir) is non-inferior to a twice-daily dose in suppressing viral load in treatment-experienced HIV-1 infected patients in a Phase III study.
The data were presented last week at the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Gilead's HIV Quad meets primary endpoint, but not investors' expectations
- Positive Phase III results confirm Q2 2012 filing for Gilead's HIV drug booster, cobicistat
- Gilead's 2nd positive Phase III sets up early FDA submission for Quad
- Positive PhIII data from Gilead's elvitegravir stands up at two years
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
